Buprenorphine

Major

Buprenorphine Sulpiride Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Sultopride Explained An increased risk of QT interval prolongation Details Buprenorphine Sumatriptan Imitrex Explained An increased risk of serotonin syndrome Details Buprenorphine Sunitinib Sutent Explained An increased risk of QT interval prolongation Details Buprenorphine Suvorexant Belsomra Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Tacrolimus Astagraf Explained An increased risk of QT interval prolongation Details Buprenorphine Taletrectinib Ibtrozi Explained Increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Tamoxifen Nolvadex® Explained An increased risk of QT interval prolongation Details Buprenorphine Tapentadol Nucynta Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome, respiratory depress... Details Buprenorphine Tazemetostat Tazverik Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Buprenorphine Tedizolid Phosphate Sivextro Explained An increased risk of serotonin syndrome Details Buprenorphine Telaprevir Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Telavancin Vibativ Explained An increased risk of QT interval prolongation Details Buprenorphine Telithromycin Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Telotristat Ethyl Xermelo Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Temazepam Restoril Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Terodiline Explained An increased risk of paralytic ileus Details Buprenorphine Tetrabenazine Xenazine Explained An increased risk of QT interval prolongation Details Buprenorphine Tetrazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Thiethylperazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Thiopental Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Thiopropazate Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Thioridazine Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine, an increased risk of QT interval prolongation, an increased ris... Details Buprenorphine Thiothixene Explained Increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Tianeptine Explained An increased risk of serotonin syndrome Details Buprenorphine Ticagrelor Brilinta Explained Reduced absorption of ticagrelor Details Buprenorphine Tilidine Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Tiotropium Explained An increased risk of paralytic ileus Details Buprenorphine Tizanidine Explained Enhanced neuromuscular blocking action, an increased risk of respiratory depression and CNS depression and an increased risk of pa... Details Buprenorphine Tolonium Chloride Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Tolterodine Detrol Explained An increased risk of paralytic ileus and an increased risk of QT interval prolongation Details Buprenorphine Topiramate Eprontia Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Toremifene Fareston Explained An increased risk of QT interval prolongation Details Buprenorphine Torsemide Soaanz Explained Reduced efficacy of diuretics Details Buprenorphine Tramadol ConZip Explained Reduced efficacy of traMADol, an increased risk of withdrawal symptoms, an increased risk of serotonin syndrome and an increased r... Details Buprenorphine Trazodone Raldesy Explained Increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of CNS depression Details Buprenorphine Triamterene Dyrenium Explained Reduced efficacy of diuretics Details Buprenorphine Triazolam Halcion Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Trichlormethiazide Explained Reduced efficacy of diuretics Details Buprenorphine Triclabendazole Egaten Explained An increased risk of QT interval prolongation Details